Skip to main content
NIH funding notice RFA-CA-22-004

Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

Closed on September 22, 2022.

Posted
November 3, 2021
Close date
September 22, 2022
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $834,586 in first-year total cost, median $329,045.

Most frequent study sections

  1. Special Emphasis Panel[ZCA1 TCRB-5 (J1)]2
  2. Special Emphasis Panel[ZCA1 TCRB-J (M1)]1

Most frequent institutions

  1. NORTH CAROLINA STATE UNIVERSITY RALEIGH1
  2. UNIVERSITY OF CALIFORNIA AT DAVIS1
  3. WASHINGTON UNIVERSITY1
Competing awards under RFA-CA-22-004 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2023A Rapid and Comprehensive Approach for Clinical Genomic Profiling in Lung Cancer1R33CA278510-01DUNCAVAGE, ERIC JSPENCER, DAVID HWASHINGTON UNIVERSITY, MO$388,026ZCA1
2023CoreView and FIBI for rapid-onsite evaluation and molecular profiling of core-needle breast biopsies.1R33CA278544-01LEVENSON, RICHARD M.UNIVERSITY OF CALIFORNIA AT DAVIS, CA$329,045ZCA1
2023MASTER Scaffolds for Rapid, Single-Step Manufacture and Prototyping of CAR-T cells1R33CA281875-01BRUDNO, YEVGENYNORTH CAROLINA STATE UNIVERSITY RALEIGH, NC$117,515ZCA1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

RFA-CA-22-004: Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) | ScienceDex | ConductScience